查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1654650

全球疼痛管理設備市場 - 2025 年至 2033 年

Global Pain Management Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球疼痛管理設備市場規模達到 38 億美元，預計到 2033 年將達到 83 億美元，在 2025-2033 年預測期內的複合年成長率為 9.2%。

疼痛管理設備是一種專門的醫療工具，旨在緩解慢性和急性疼痛，改善患者生活品質，減少對鴉片類藥物等藥物治療的依賴。這些設備採用各種技術，包括電刺激、熱療、冷凍療法和藥物傳遞系統，針對疼痛源頭並直接或間接地緩解疼痛。

疼痛管理設備在現代醫療保健中發揮著至關重要的作用，它為傳統方法可能不足或有重大風險的情況（例如鴉片類藥物成癮）提供有效的解決方案。它們使患者能夠更好地控制疼痛並提高臨床和家庭環境中疼痛管理的效率。

全球疼痛管理設備市場正在經歷顯著成長，推動因素包括慢性疼痛病症的日益普及、技術進步以及對非侵入性治療方案的日益偏好。例如，根據美國疾病管制與預防中心 (CDC) 的數據，2021 年，估計有 20.9% 的美國成年人（5,160 萬人）患有慢性疼痛，6.9%（1710 萬人）患有高強度慢性疼痛，這推動了對有效疼痛管理設備的需求。

市場動態：

促進因素與約束因素

疼痛管理設備的技術進步日新月異

疼痛管理設備的技術進步極大地推動了疼痛管理設備市場的成長，並預計在預測期內推動市場的發展。脊髓刺激和周邊神經刺激等技術正變得越來越先進，可以透過精確控制刺激參數來提供有針對性的疼痛緩解。這些進步不僅可以緩解疼痛，而且透過提供更個人化的設定還可以提高患者的滿意度。

例如，2023 年 1 月，雅培獲得美國食品藥物管理局 (FDA) 批准其 Proclaim XR 脊髓刺激 (SCS) 系統用於治療糖尿病的一種嚴重併發症—疼痛性糖尿病周邊神經病變 (DPN)。 Proclaim XR SCS 系統可為需要傳統治療方法（例如口服藥物）替代療法的 DPN 患者提供緩解。接受 Proclaim XR SCS 系統治療的人還可以使用雅培的 NeuroSphere 虛擬診所，這是一款聯網護理應用程式，可讓人們與醫生溝通並遠端接受治療調整。

人工智慧在疼痛管理設備中的應用正在推動個人化治療方案。這些技術即時分析患者資料，調整設備參數以達到最佳的疼痛緩解效果。例如，2024 年 9 月，Nevro Corp. 宣布美國食品藥物管理局 (FDA) 批准並在有限市場上發布配備 HFX AdaptivAI 的 HFX iQ，這是脊髓刺激領域唯一的人工智慧驅動技術，是一種響應式個人化疼痛管理平台，為 HFX iQ 脊髓刺激 (SCS) 系統提供動力。

由於影像和導引系統技術的進步，微創和非侵入性手術正在成為常態。例如，2024 年 9 月，Zynex Inc. 宣布其新款 TensWave 裝置已獲得 FDA 批准。 TensWave 設備僅憑處方購買，它繼承了 Zynex 在疼痛管理領域的強大創新傳統。它採用方便用戶使用的攜帶式設計，可以輕鬆融入患者的日常生活。該設備旨在透過 TENS（經皮神經電刺激）療法有效緩解疼痛，臨床證明該療法無需藥物即可減輕慢性和急性疼痛。

疼痛管理設備成本高昂

預計疼痛管理設備的高成本將在預測期內阻礙市場的成長。脊髓刺激器、神經刺激裝置和輸液幫浦等先進疼痛管理設備的費用對許多患者來說是難以負擔的。這些設備通常需要預付款，超出了許多人的承受能力，特別是在那些此類設備保險覆蓋範圍有限或沒有保險的國家。

例如，根據美國醫生合作夥伴協會的數據，脊髓刺激器的價格根據實際情況在 7,000 美元至 10,000 美元之間。此外，波士頓科學脊髓刺激器新款售價約為 19,000 美元。

這些設備（特別是深部腦部刺激設備和程序）的成本高昂，是阻礙市場成長的重要因素，因為它限制了大量潛在患者獲得治療的機會和負擔能力。這一財務障礙影響了採用率，特別是在中低收入地區，並且影響了醫療保健提供者和患者。

例如，根據美國國立衛生研究院 2024 年的數據，經通貨膨脹和貨幣調整後的 DBS 設備平均成本為 21,496.07 美元 +- 8,944.16 美元，僅手術費用就為 14,685.22 美元 +- 8,479.66 美元，手術總費用為 4857.507, 3800 美元為 47,632.27 美元 +- 23,067.08 美元。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 疼痛管理設備的技術進步日新月異
    • 限制
      • 疼痛管理設備成本高昂
    • 機會
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • 新興創業公司和關鍵創新者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：疼痛管理設備市場（依產品類型）

  • 神經刺激裝置
    • 脊髓刺激器
    • 周邊神經刺激器
    • 深部腦部刺激器
  • 消融設備
    • 冷凍消融設備
    • 射頻消融設備
  • 點滴幫浦
  • 電刺激裝置

第 6 章：疼痛管理設備市場（按應用）

  • 神經性疼痛
  • 癌症疼痛
  • 肌肉骨骼疼痛
  • 偏頭痛
  • 其他

第 7 章：疼痛管理設備市場（以最終用戶分類）

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 物理治療中心
  • 其他

第 8 章：疼痛管理設備市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Medtronic plc
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 關鍵進展
    • SWOT 分析
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Stryker Corporation
  • Nevro Corp
  • Aleva Neurotherapeutics
  • Zynex Inc.
  • ICU Medical, Inc.
  • inomed Medizintechnik GmbH
  • Enovis Corporation

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: PH8938

The global pain management devices market reached US$ 3.8 billion in 2024 and is expected to reach US$ 8.3 billion by 2033, growing at a CAGR of 9.2% during the forecast period 2025-2033.

Pain management devices are specialized medical tools designed to alleviate chronic and acute pain, improve patient quality of life, and reduce dependency on pharmacological treatments such as opioids. These devices employ various technologies, including electrical stimulation, heat therapy, cryotherapy, and drug delivery systems, to target pain at its source and provide relief either directly or indirectly.

Pain management devices play a crucial role in modern healthcare by providing effective solutions for conditions where traditional methods may be insufficient or carry significant risks, such as opioid addiction. They empower patients with better control over their pain and enhance the efficiency of pain management in clinical and home settings.

The global pain management devices market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic pain conditions, technological advancements and a growing preference for non-invasive treatment options. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain, driving the demand for effective pain management devices.

Market Dynamics: Drivers & Restraints

Rising technological advancements in pain management devices

The rising technological advancements in pain management devices are significantly driving the growth of the Pain Management Devices market and are expected to drive the market over the forecast period. Technologies like Spinal Cord Stimulation and Peripheral Nerve Stimulation are becoming more advanced, providing targeted pain relief with precise control over stimulation parameters. These advancements not only improve pain relief but also enhance patient satisfaction by allowing more personalized settings.

For instance, in January 2023, Abbott cleared the U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.

The use of AI in pain management devices is driving personalized treatment plans. These technologies analyze patient data in real time, adjusting device parameters for optimal pain relief. For instance, in September 2024, Nevro Corp. announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI, the Only AI-driven technology in spinal cord stimulation, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.

Minimally invasive and non-invasive procedures are becoming the norm due to technological advancements in imaging and guidance systems. For instance, in September 2024, Zynex Inc. announced FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management. It offers a user-friendly, portable design that can be easily integrated into patients' daily routines. The device aims to provide effective pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which has been clinically proven to reduce chronic and acute pain without needing medication.

High cost of pain management devices

The high cost of pain management devices is expected to hamper the growth of the market over the forecast period. The cost of advanced pain management devices such as spinal cord stimulators, neurostimulation devices, and infusion pumps can be prohibitive for many patients. These devices often require upfront payments that are beyond the reach of many individuals, especially in countries where insurance coverage for such devices is limited or nonexistent.

For instance, according to the Physician Partners of America, the price for a spinal cord stimulator ranges from $7,000-$10,000 depending on the practice. Additionally, a Boston Scientific Spinal Cord Stimulator costs around $19,000 for newer models.

The high cost of these devices especially fro deep brain stimulation devices and procedures is a significant factor that hampers market growth by limiting access and affordability for a large segment of potential patients. This financial barrier affects adoption rates, particularly in low- and middle-income regions and impacts both healthcare providers and patients.

For instance, according to the National Institute of Health, 2024, the inflation and currency-adjusted mean cost of the DBS device was USD 21,496.07 +- USD 8,944.16, the cost of surgery alone was USD 14,685.22 +- USD 8,479.66, the total cost of surgery was USD 40,942.85 +- USD 17,987.43 and the total cost of treatment until 1 year of follow-up was USD 47,632.27 +- USD 23,067.08.

Segment Analysis

The global pain management devices market is segmented based on product type, application, end-user and region.

Product Type:

The neurostimulation devices segment is expected to dominate the pain management devices market share

Neurostimulation devices, such as Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS), are highly effective in managing chronic pain by targeting specific pain pathways. This targeted approach allows for customized treatment settings that adapt to the patient's specific pain pattern.

For instance, in January 2024, Abbott received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC DBS system, the world's smallest rechargeable deep brain stimulation (DBS) device with remote programming. The Liberta RC DBS system requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.

Neurostimulation devices are used to treat a broad spectrum of chronic pain conditions, including neuropathic pain, back pain, post-surgical pain, and migraine. For instance, in February 2024, Boston Scientific Corporation cleared U.S. Food and Drug Administration (FDA) approval for an expanded indication of the WaveWriter SCS Systems for the treatment of chronic low back and leg pain in people without prior back surgery, commonly referred to as non-surgical back pain (NSBP). The versatility of neurostimulation devices contributes to their dominance in the market as they cater to multiple patient needs with different pain profiles.

Advances in neurostimulation technology, such as minimally invasive implantation techniques, have made these devices more accessible and less intimidating for patients. The devices with a wearable approach that can be adjusted via smartphone, make it user-friendly and more acceptable to patients who may otherwise be resistant to invasive surgery.

For instance, in April 2023, Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, announced that it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation therapy through a wireless platform including a wearable transmitter and iPad-based clinician programmer.

Geographical Analysis

North America is expected to hold a significant position in the pain management devices market share

North America especially the United States is home to several major players in the pain management devices market, including Medtronic, Stryker Corporation, Boston Scientific, Abbott and other emerging players. These companies have extensive R&D operations in the region, focusing on the development of advanced pain management solutions, resulting in innovations, which integrate advancements for personalized pain management.

For instance, in April 2024, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real-time, keeping therapy in harmony with the motions of daily life.

Additionally, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain. MultiGen 2 is the next generation of radiofrequency ablation that provides physicians with control and customization to perform chronic pain management procedures with confidence.

The U.S. FDA's rigorous but predictable approval process makes North America an ideal market for new pain management devices. Companies like Abbott and Boston Scientific frequently conduct pivotal clinical trials in North America to gain regulatory approval for new products. This gives North American patients early access to innovative pain relief technologies, fostering market leadership.

Asia-Pacific is growing at the fastest pace in the pain management devices market

Asia-Pacific is increasingly adapting global pain management technologies to local needs, leading to rapid market growth. For instance, the Abbott Proclaim XR system has been adapted for use in countries like India and China with specific features tailored to the local healthcare landscape. This device offers both spinal cord stimulation and peripheral nerve stimulation, making it suitable for a wide range of chronic pain conditions prevalent in the region.

The major market players and emerging players in the region developing advanced smart devices for pain management. For instance, in September 2022, UltrcareCare Pro introduced TENS 2.0, a Smart - Wearable, Wireless and Pocket-sized Pain Management Device for joint, muscular and everyday pain featuring a modern design that is truly wireless with the size of a smartwatch.

Increasing awareness of chronic pain and available treatments is driving market growth in APAC. Government and non-governmental organizations are conducting awareness campaigns about the benefits of pain management devices. For instance, in Australia, initiatives by Pain Australia have highlighted the benefits of devices like spinal cord stimulators and how they can improve the quality of life for chronic pain patients. These programs are educating both healthcare providers and patients, leading to higher adoption rates of pain management devices.

Competitive Landscape

The major global players in the pain management devices market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Stryker Corporation, Nevro Corp, Aleva Neurotherapeutics, Zynex Inc., ICU Medical, Inc., inomed Medizintechnik GmbH, Enovis Corporation and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pain management devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Pain Management Devices
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Pain Management Devices
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pain Management Devices Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Neurostimulation Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Spinal Cord Stimulators
    • 5.2.4. Peripheral Nerve Stimulators
    • 5.2.5. Deep Brain Stimulators
  • 5.3. Ablation Devices
    • 5.3.1. Cryoablation Devices
    • 5.3.2. Radiofrequency Ablation Devices
  • 5.4. Infusion Pumps
  • 5.5. Electrical Stimulation Devices

6. Pain Management Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Neuropathic Pain*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Cancer Pain
  • 6.4. Musculoskeletal Pain
  • 6.5. Migraine Pain
  • 6.6. Others

7. Pain Management Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Physiotherapy Centers
  • 7.6. Others

8. Pain Management Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.7. U.S.
    • 8.2.8. Canada
    • 8.2.9. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.7. Germany
    • 8.3.8. U.K.
    • 8.3.9. France
    • 8.3.10. Spain
    • 8.3.11. Italy
    • 8.3.12. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.7. Brazil
    • 8.4.8. Argentina
    • 8.4.9. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.7. China
    • 8.5.8. India
    • 8.5.9. Japan
    • 8.5.10. South Korea
    • 8.5.11. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Medtronic plc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Boston Scientific Corporation
  • 10.3. Abbott Laboratories
  • 10.4. Stryker Corporation
  • 10.5. Nevro Corp
  • 10.6. Aleva Neurotherapeutics
  • 10.7. Zynex Inc.
  • 10.8. ICU Medical, Inc.
  • 10.9. inomed Medizintechnik GmbH
  • 10.10. Enovis Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us